Reducing Complement Inhibition to Treat Leukemia and Lymphoma

描述（由申请人提供）：申请的资金将用于获得一种新的白血病和淋巴瘤联合癌症治疗的安全性和有效性数据。单克隆抗体（mab）已成为一类新的肿瘤治疗药物。我们正在开发一种分子，可以通过以下方式改善单克隆抗体的治疗效果：1)增加癌症对治疗的敏感性；2)揭开耐药癌症的掩体，使它们再次变得敏感；3)有可能治疗已经变得难以治疗的癌症。该项目将为未来的人体试验提供临床候选药物。单抗治疗的剂量节约和成本降低、癌症预后改善以及为以前的耐药癌症提供一种新的治疗方法对公共卫生的影响是重大的。该研究的直接目标是收集数据，以使研究新药（IND）申请淋巴瘤联合治疗。我们在华盛顿大学的顾问已经收集了大量的信息，支持将细胞表面的CD46与抗体治疗结合在血癌中的优势。我们的长期目标是将这项技术从研究台中转化为临床床边，从而增强单克隆抗体（mAb）治疗。

DESCRIPTION (provided by applicant): The funding of the application will yield safety and efficacy data on a new combination cancer therapy for leukemia and lymphomas. Monoclonal antibodies (mAbs) have emerged as a class of novel oncology therapeutics. We are developing a molecule that can improve the therapeutic effects of mAbs by: 1) increasing the sensitivity of cancers to treatment 2) unmasking resistant cancers so they again become sensitized and 3) potentially allowing treatment of cancers that have become refractory to therapy. This project will move a clinical candidate forward for future testing in humans. The public health implications of dose-sparing and cost reduction for mAb therapy, improved outcomes in cancer and making a new therapy available for previously resistant cancers are significant. The immediate goal of the research is to collect data to enable an Investigational New Drug (IND) filing on a combination therapy for lymphoma. Our consultant at the University of Washington has collected a significant body of information supporting the superiority of the combination of depleting CD46 on the cell surface with antibody therapy in blood cancers Our long-term goal is to translate the technology from research bench to clinical bedside leading to enhancement of monoclonal antibody (mAb) therapy. PUBLIC HEALTH RELEVANCE: Although monoclonal antibody therapy can be an effective way to treat cancer, further progress is needed to increase therapeutic success. We intend to enhance cancer therapy to improve treatment worldwide.